Senecavirus

Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Syngenic, Immune system, NSCLC, Congress, Non-small-cell lung carcinoma, Glioblastoma, RCC, RNA, Cancer, IND, Large-cell lung carcinoma, SCLC, Renal cell carcinoma, Squamous cell carcinoma, Patient, Melanoma, Burn, SVV, Annual report, EGFR, Workforce, Genome, Wilms' tumor, Senecavirus, Nature Communications, Security (finance), GEMM, Mouse, HCC, Hepatocellular carcinoma, IV, RNA transfection, CVA21, Immunotherapy, Investment, Safety, Vaccine, Pharmaceutical industry, PDX, LNP

As part of this reprioritization, we are discontinuing the Phase 1 trial of ONCR-177 to focus our resources on ONCR-021.

Key Points: 
  • As part of this reprioritization, we are discontinuing the Phase 1 trial of ONCR-177 to focus our resources on ONCR-021.
  • Oncorus will present the results of the Phase 1 study of ONCR-177 in patients with advanced disease in conjunction with a scientific congress in 2023.
  • ONCR-021 is Oncorus lead candidate from its self-amplifying RNA platform intended to allow for intravenous (IV) administration.
  • At Oncorus, we are focused on driving innovation in RNA medicines by developing next-generation immunotherapies to stimulate the immune system and transform outcomes for cancer patients.

Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

Retrieved on: 
Friday, October 7, 2022
SVV, U.S. Securities and Exchange Commission, RNA transfection, HSV, Renal cell carcinoma, Transgene, Therapy, Syngenic, SEC, Investor, IND, Virus, Neoplasm, Annual report, Patient, IV, Hepatocellular carcinoma, RNA, Security (finance), Program, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SCLC, Nasdaq, GEMM, Cancer, Private Securities Litigation Reform Act, Mouse, Immune system, Company, Large-cell lung carcinoma, Research, Safety, GLOBE, Melanoma, Nature Communications, CVA21, FDA, COVID-19, LNP, Risk, Vaccine, PDX, Senecavirus, Young LNP

The article describes the design and development of Oncorus synthetic RNA viruses for the systemic treatment of cancer.

Key Points: 
  • The article describes the design and development of Oncorus synthetic RNA viruses for the systemic treatment of cancer.
  • By encapsulating vRNA in LNPs, Oncorus was able to recapitulate oncolytic viral therapy in various tumor cells and avoid neutralizing antibodies.
  • The vRNA/LNP constructs were well tolerated and elicited tumor-specific in situ production of oncolytic virions, immune cell recruitment and tumor destruction.
  • Overall, synthetic RNA viruses were well tolerated after a single or multiple IV dose in mice and non-human primates.

Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I/II Clinical Study

Retrieved on: 
Monday, October 3, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Senecavirus, Patient, Forward-looking statement, Seneca, SVV, Neuroendocrine carcinoma of the cervix, Wilms' tumor, Therapy, FDA, Neoplasm, Genome, Pharmaceutical industry

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers announced today it had received FDA clearance to begin a Phase I/II clinical study utilizing Seneca Valley Virus (SVV-001) in combination with a checkpoint inhibitor.

Key Points: 
  • Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers announced today it had received FDA clearance to begin a Phase I/II clinical study utilizing Seneca Valley Virus (SVV-001) in combination with a checkpoint inhibitor.
  • This Phase I/II study with SVV-001 is in patients that are TEM8 positive and SVV-001 permissive with neuroendocrine tumors or neuroendocrine carcinomas.
  • The study should begin enrollment early in 2023.
  • This press release contains forward-looking statements concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the companys expectations regarding its prospects.

Seneca Therapeutics, Inc. to Present at the World Vaccine Congress in Washington, DC April 18-21, 2022

Retrieved on: 
Monday, April 18, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Carcinoma, STI, Research, Doctor of Philosophy, SVV, Seneca, Patient, Neoplasm, Genome, Neuroendocrine tumor, Forward-looking statement, Senecavirus, Safety, Therapy, Congress, Pharmaceutical industry

Seneca Therapeutics, Inc. (STI), a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers will be presenting on Wednesday, April 20 at 12:10pm at the World Vaccine Congress in Washington, DC.

Key Points: 
  • Seneca Therapeutics, Inc. (STI), a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers will be presenting on Wednesday, April 20 at 12:10pm at the World Vaccine Congress in Washington, DC.
  • Seneca Therapeutics Senior Immunology Consultant, Michael Lacy, PhD will present a summary of prior research and three clinical trials done utilizing Seneca Valley Virus (SVV-001) delivered intravenously as a monotherapy.
  • Dr. Lacy will also discuss Senecas upcoming Phase I/II clinical trial in both Neuroendocrine tumor and carcinoma patients.
  • Finally, data will also be presented demonstrating the utility of SVV to express therapeutic transgenes (armed derivatives) and/or cancer antigens.

Oncorus Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting

Retrieved on: 
Friday, April 8, 2022
RCC, Private Securities Litigation Reform Act, PDX, Therapy, Degenerative disease, Investor, Orthornavirae, IND, AACR, Risk, Immunotherapy, Tropism, American Association, Neoplasm, Cancer, Mark (given name), RNA, U.S. Securities and Exchange Commission, NSCLC, Renal cell carcinoma, Food, Security (finance), Genome, Immune system, Association, American Association for Cancer Research, Safety, RNA transfection, Transgene, CDX, HSV, Nasdaq, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Melanoma, Myelocyte, SVV, Senecavirus, CVA21, Wilms' tumor, LNP, Annual report, FDA, Potyvirus, PD-L1, GEMM, Patient, Large-cell lung carcinoma, IV, Pharmaceutical industry, Vaccine

CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced its presentation of preclinical data for both ONCR-021 and ONCR-788 in two e-posters at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13 in New Orleans, Louisiana, supporting the company’s selectively self-amplifying viral RNA (vRNA) Immunotherapy Platform.

Key Points: 
  • The preclinical data presented on ONCR-021 and ONCR-788 at AACR are an important step forward for Oncorus novel approach of selectively self-amplifying vRNA immunotherapies formulated in lipid nanoparticles.
  • Oncorus vRNA Immunotherapy Platform encapsulates the genomes of RNA viruses known to kill cancer cells within an LNP, producing a living oncolytic and immunostimulatory viral infection in the tumor to destroy cancer cells and stimulate the immune system.
  • In preclinical studies, Oncorus IV-administered vRNA immunotherapies demonstrated efficacy in multiple tumor models, avoiding the challenges seen in previous studies incorporating IV administration of RNA-based oncology therapeutics.
  • Designed to deliver next-generation viral immunotherapy impact, our HSV Platform improves upon key characteristics of this therapeutic class to enhance systemic activity.

Seneca Therapeutics To Host a Key Opinion Leader Webinar on Seneca Valley Virus and TEM 8 On Wednesday, March 16th @ 2pmET

Retrieved on: 
Thursday, March 10, 2022
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, University, Survival, Eastern Time Zone, Senecavirus, Cancer, Seneca, Genome, KOL, Patient, Therapy, SVV, History, Forward-looking statement

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics based on Seneca Valley Virus (SVV-001), announced today that it will host a key opinion leader (KOL) webinar titled Seneca Valley Virus and TEM8 on Wednesday, March 16, 2022 at 2:00pm Eastern Time.

Key Points: 
  • Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics based on Seneca Valley Virus (SVV-001), announced today that it will host a key opinion leader (KOL) webinar titled Seneca Valley Virus and TEM8 on Wednesday, March 16, 2022 at 2:00pm Eastern Time.
  • Dr. Bostina will discuss the unique characteristics and exquisite solid tumor specificity of SVV-001 in the treatment of solid cancers.
  • He will also discuss the mechanism of SVV receptor selectivity, specifically TEM8, an integrin expressed primarily on the surface of solid tumor cells.
  • Dr. Paul Hallenbeck, President and Chief Scientific Officer at Seneca Therapeutics will give a brief presentation on the history of SVV-001.

Seneca Therapeutics Announces Publication of AACR Abstract Demonstrating Systemic Anti-Tumor Immune Response in Syngeneic Pancreatic Murine Model

Retrieved on: 
Wednesday, March 9, 2022
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Genome, Forward-looking statement, Pancreatic cancer, Senecavirus, Therapy, American Association, Association, Seneca, American Association for Cancer Research

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of oncolytic immune-therapeutics based on Seneca Valley Virus (SVV-001), announced today the publication of an abstract Oncolytic Seneca Valley Virus (SVV-001) overcomes checkpoint inhibitor resistance and demonstrates a systemic anti-tumor immune response in a syngeneic pancreatic cancer murine model at the upcoming American Association for Cancer Research meeting in New Orleans, LA.

Key Points: 
  • Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of oncolytic immune-therapeutics based on Seneca Valley Virus (SVV-001), announced today the publication of an abstract Oncolytic Seneca Valley Virus (SVV-001) overcomes checkpoint inhibitor resistance and demonstrates a systemic anti-tumor immune response in a syngeneic pancreatic cancer murine model at the upcoming American Association for Cancer Research meeting in New Orleans, LA.
  • The abstract will be presented by Dr. Paul Hallenbeck, one of the authors of the publication.
  • Seneca Therapeutics was founded by Dr. Paul Hallenbeck to develop SVV-001.
  • This press release contains forward-looking statements concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the companys expectations regarding its prospects.

Oncorus Reports Third Quarter 2021 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, November 3, 2021
Immunotherapy, IV, RNA transfection, Neoplasm, Learning, Brain, Society, GBM, OVS, Clinical trial, COVID-19, Program, DC, Process, GLOBE, SITC, Synthetic, Lung, Herpes simplex virus, Research, Poster, Quality control, Potyvirus, Insurance, Private Securities Litigation Reform Act, RNA, Income, Annual report, Risk, Mark (given name), Senecavirus, GLP, GMP, PD-1, CMC, Transgene, Growth, SVV, Novel, Nasdaq, Pembrolizumab, Glioblastoma, Annual general meeting, IPO, Cancer, Patient, Investor, Efficacy, Orthornavirae, Conference, MicroRNA, Young LNP, Vaccine, Cryptocurrency, Pharmaceutical industry

This presentation at SITC will mark Oncorus first reporting of human data from its oHSV platform.

Key Points: 
  • This presentation at SITC will mark Oncorus first reporting of human data from its oHSV platform.
  • Research and development expenses for the quarter ended September 30, 2021 were $11.3 million compared to $6.9 million for the corresponding quarter in 2020.
  • General and administrative expenses for the quarter ended September 30, 2021 were $5.4 million compared to $2.0 million for the corresponding quarter in 2020.
  • Other income (expense), net, for the quarter endedSeptember 30, 2021 was income of $0.01 million compared to an expense of$10.6 millionfor the quarter ended September 30, 2020.

Seneca Therapeutics, Inc. Announces Launch of a Novel Cancer Gene Delivery Platform based on SVV-001 Technology

Retrieved on: 
Tuesday, September 21, 2021
Science, Other Science, Biotechnology, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Therapy, Cancer, Neoplasm, CSO, Genome, Senecavirus, Patient, Transgene, SVV, Gene, Seneca, Potyvirus, Forward-looking statement, STI, Vaccine

Seneca Therapeutics, Inc. (STI), a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics for cancer based on Seneca Valley Virus (SVV-001), announced today the launch of a novel Cancer Gene Delivery Platform based on SVV-001 technology.

Key Points: 
  • Seneca Therapeutics, Inc. (STI), a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics for cancer based on Seneca Valley Virus (SVV-001), announced today the launch of a novel Cancer Gene Delivery Platform based on SVV-001 technology.
  • STI has a wealth of data, including from three clinical trials that SVV-001 is amongst the most cancer selective oncolytic viruses.
  • STI has now demonstrated that genes to enhance cancer therapy can easily be inserted into SVV-001.
  • Because SVV-001 is a natural, non-human virus, the manufacturing process to produce SVV-001 Armed Gene Constructs is much simpler, faster, and significantly less expensive than current virus or gene therapy vectors used in cancer gene delivery.

Seneca Therapeutics, Inc. Announces Novel SVV-001 Patient Screening Test For Patient Selection With SVV-001 Therapy

Retrieved on: 
Tuesday, September 14, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Cancer, Therapy, Senecavirus, Forward-looking statement, Arme Construction Company, Patient, Gene, Genome, Sarcoma, Laboratory, Founder, CLIA, CSO, Seneca, Intravenous therapy, Medical imaging, Pharmaceutical industry

The SVV-001 Patient Screening Test can be used on Formalin-Fixed-Paraffin-Embedded (FFPE) tumor blocks allowing for patient screening using previous biopsies.

Key Points: 
  • The SVV-001 Patient Screening Test can be used on Formalin-Fixed-Paraffin-Embedded (FFPE) tumor blocks allowing for patient screening using previous biopsies.
  • The SVV-001 Patient Screening Test can also be used to identify types of cancer patients that will benefit from SVV-001.
  • The selection of patients using the SVV-001 Patient Screening Test will be applicable whether the patient is treated with either the Intra-tumoral or Intravenous route of administration.
  • Seneca Therapeutics is also using the SVV-001 Patient Screening Test to identify relevant cancer patient populations that could benefit from SVV-001 therapy.